Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Flavopiridol Elicits Poor Response in Mantle Cell Lymphoma, DLBCL

Key clinical point: The novel CDK inhibitor flavopiridol showed minimal efficacy in patients with relapsed/refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and other B-cell lymphomas.

Major finding: Of 26 evaluable patients, one patient with DLBCL maintained a partial response for 84 days (overall response rate, 3.8%).

Study details: A phase 1/2 study of 28 patients with relapsed/refractory MCL and DLBCL.

Disclosures: The trial is sponsored by the National Cancer Institute, and the study authors are employees of the National Cancer Institute.

Citation:

Miljkovic MD et al. Leuk Lymphoma. 2019 Jun 17. doi: 10.1080/10428194.2019.1627540.